tiprankstipranks
Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
Company Announcements

Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO

Don't Miss our Black Friday Offers:

The latest update is out from Prelude Therapeutics ( (PRLD) ).

Prelude Therapeutics has announced its presentation of clinical data on PRT3789, a groundbreaking treatment for cancers with SMARCA4 mutations, at the ESMO Congress 2024. This novel SMARCA2 degrader has shown promise in Phase 1 trials, demonstrating safety and potential efficacy, with Phase 2 dose recommendations expected by year-end. Prelude is also hosting an investor webcast to discuss these advancements, indicating a significant step forward in precision oncology.

See more data about PRLD stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPrelude Therapeutics Reports Progress in Clinical Trials and Financial Health
TipRanks Auto-Generated NewsdeskPrelude Therapeutics Shows Strong Q3 2024 Financial Results
TheFlyPrelude Therapeutics reports Q3 EPS (43c), consensus (47c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App